CORESTEM Inc - Asset Resilience Ratio

Latest as of September 2025: 3.80%

CORESTEM Inc (166480) has an Asset Resilience Ratio of 3.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 166480 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩4.30 Billion
≈ $2.92 Million USD Cash + Short-term Investments

Total Assets

₩113.27 Billion
≈ $76.76 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how CORESTEM Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 166480 current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down CORESTEM Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore CORESTEM Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩4.30 Billion 3.8%
Total Liquid Assets ₩4.30 Billion 3.80%

Asset Resilience Insights

  • Limited Liquidity: CORESTEM Inc maintains only 3.80% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

CORESTEM Inc Industry Peers by Asset Resilience Ratio

Compare CORESTEM Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Dianthus Therapeutics Inc.
NASDAQ:DNTH
Biotechnology 63.98%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 62.24%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%
Wecome Pharmaceutical Co Ltd
SHE:300878
Biotechnology 0.67%
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Biotechnology 86.66%
Relmada Therapeutics Inc
NASDAQ:RLMD
Biotechnology 95.25%
MediWound Ltd
F:M8W
Biotechnology 56.04%

Annual Asset Resilience Ratio for CORESTEM Inc (2014–2024)

The table below shows the annual Asset Resilience Ratio data for CORESTEM Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 1.89% ₩2.22 Billion
≈ $1.51 Million
₩117.46 Billion
≈ $79.60 Million
-1.55pp
2023-12-31 3.44% ₩2.70 Billion
≈ $1.83 Million
₩78.59 Billion
≈ $53.26 Million
+0.14pp
2022-12-31 3.30% ₩2.59 Billion
≈ $1.76 Million
₩78.61 Billion
≈ $53.28 Million
-47.10pp
2021-12-31 50.40% ₩68.75 Billion
≈ $46.59 Million
₩136.41 Billion
≈ $92.44 Million
-15.04pp
2020-12-31 65.43% ₩93.49 Billion
≈ $63.35 Million
₩142.87 Billion
≈ $96.82 Million
+29.59pp
2019-12-31 35.85% ₩30.70 Billion
≈ $20.81 Million
₩85.65 Billion
≈ $58.04 Million
+20.72pp
2018-12-31 15.12% ₩13.50 Billion
≈ $9.15 Million
₩89.26 Billion
≈ $60.49 Million
+7.95pp
2017-12-31 7.17% ₩6.50 Billion
≈ $4.40 Million
₩90.67 Billion
≈ $61.45 Million
+0.61pp
2016-12-31 6.56% ₩5.62 Billion
≈ $3.81 Million
₩85.69 Billion
≈ $58.07 Million
+4.56pp
2015-12-31 2.00% ₩1.50 Billion
≈ $1.02 Million
₩74.95 Billion
≈ $50.80 Million
-20.51pp
2014-12-31 22.51% ₩8.10 Billion
≈ $5.49 Million
₩35.99 Billion
≈ $24.39 Million
--
pp = percentage points

About CORESTEM Inc

KQ:166480 Korea Biotechnology
Market Cap
$39.60 Million
₩58.44 Billion KRW
Market Cap Rank
#22863 Global
#1511 in Korea
Share Price
₩2080.00
Change (1 day)
-1.42%
52-Week Range
₩1060.00 - ₩4800.00
All Time High
₩32150.00
About

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more